Abbott präsentiert positive Studiendaten zur Volt™ Pulsed Field Ablation bei Vorhofflimmern

Reuters

Feb 06

Abbott präsentiert positive Studiendaten zur Volt™ Pulsed Field Ablation bei Vorhofflimmern

Abbott Laboratories hat neue klinische Daten zu zwei minimal-invasiven Therapien zur Behandlung von Vorhofflimmern (AFib) vorgestellt. Die Ergebnisse wurden im Rahmen von zwei späten Präsentationen auf dem AF Symposium in Boston (5.–7. Februar 2026) präsentiert. Die 12-Monats-Ergebnisse der VOLT-AF IDE-Studie bestätigen die langfristige Sicherheit und Leistungsfähigkeit des Volt™ Pulsed Field Ablation (PFA) Systems. Zusätzlich wurden positive Daten zur Sicherheit und Wirksamkeit des TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, aus der FOCALFLEX CE Mark Studie vorgestellt. Eine weitere Präsentation zu Abbott's Amulet Gerät aus der VERITAS Amulet 360 Pivotal Study ist für den 6. Februar 2026 geplant.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG81045) on February 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609595904"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609595904\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609595904?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609595904","market":"nz","top_or_hot":-1,"title":"Abbott präsentiert positive Studiendaten zur Volt™ Pulsed Field Ablation bei Vorhofflimmern","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Abbott präsentiert positive Studiendaten zur Volt™ Pulsed Field Ablation bei Vorhofflimmern\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Abbott Laboratories hat neue klinische Daten zu zwei minimal-invasiven Therapien zur Behandlung von Vorhofflimmern (AFib) vorgestellt. Die Ergebnisse wurden im Rahmen von zwei späten Präsentationen auf dem AF Symposium in Boston (5.–7. Februar 2026) präsentiert. Die 12-Monats-Ergebnisse der VOLT-AF IDE-Studie bestätigen die langfristige Sicherheit und Leistungsfähigkeit des Volt™ Pulsed Field Ablation (PFA) Systems. Zusätzlich wurden positive Daten zur Sicherheit und Wirksamkeit des TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, aus der FOCALFLEX CE Mark Studie vorgestellt. Eine weitere Präsentation zu Abbott's Amulet Gerät aus der VERITAS Amulet 360 Pivotal Study ist für den 6. Februar 2026 geplant.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG81045) on February 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbott präsentiert positive Studiendaten zur Volt™ Pulsed Field Ablation bei Vorhofflimmern</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbott präsentiert positive Studiendaten zur Volt™ Pulsed Field Ablation bei Vorhofflimmern\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Abbott präsentiert positive Studiendaten zur Volt™ Pulsed Field Ablation bei Vorhofflimmern\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Abbott Laboratories hat neue klinische Daten zu zwei minimal-invasiven Therapien zur Behandlung von Vorhofflimmern (AFib) vorgestellt. Die Ergebnisse wurden im Rahmen von zwei späten Präsentationen auf dem AF Symposium in Boston (5.–7. Februar 2026) präsentiert. Die 12-Monats-Ergebnisse der VOLT-AF IDE-Studie bestätigen die langfristige Sicherheit und Leistungsfähigkeit des Volt™ Pulsed Field Ablation (PFA) Systems. Zusätzlich wurden positive Daten zur Sicherheit und Wirksamkeit des TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, aus der FOCALFLEX CE Mark Studie vorgestellt. Eine weitere Präsentation zu Abbott's Amulet Gerät aus der VERITAS Amulet 360 Pivotal Study ist für den 6. Februar 2026 geplant.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG81045) on February 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BJJMRZ35.SGD","symbol_name":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL6g31ZQ:1","article_id":"2609595904","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609595904","pubTimestamp":1770382845,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Abbott Laboratories hat neue klinische Daten zu zwei minimal-invasiven Therapien zur Behandlung von Vorhofflimmern  vorgestellt. Die Ergebnisse wurden im Rahmen von zwei spten Prsentationen auf dem AF Symposium in Boston  prsentiert. Die 12-Monats-Ergebnisse der VOLT-AF IDE-Studie besttigen die langfristige Sicherheit und Leistungsfhigkeit des Volt Pulsed Field Ablation  Systems. Zustzlich wurden positive Daten zur Sicherheit und Wirksamkeit des TactiFlex Duo Ablation Catheter, Sensor Enabled, aus der FOCALFLEX CE Mark Studie vorgestellt. Eine weitere Prsentation zu Abbott's Amulet Gert aus der VERITAS Amulet 360 Pivotal Study ist für den 6. Februar 2026 geplant.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories publis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","BK4585":"ETF&股票定投概念","SG9999002224.SGD":"Allianz Global High Payout SGD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4566":"资本集团","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4082":"医疗保健设备","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4592":"伊斯兰概念","BK4504":"桥水持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4568":"美国抗疫概念","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","ABT":"雅培","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","SG9999002232.USD":"Allianz Global High Payout USD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","BK4581":"高盛持仓"},"translate_title":"雅培公布Volt的积极研究数据™脉冲场消融治疗心房颤动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT":0.9},"content_text":"Abbott präsentiert positive Studiendaten zur Volt™ Pulsed Field Ablation bei Vorhofflimmern\n    \n\n        Abbott Laboratories hat neue klinische Daten zu zwei minimal-invasiven Therapien zur Behandlung von Vorhofflimmern (AFib) vorgestellt. Die Ergebnisse wurden im Rahmen von zwei späten Präsentationen auf dem AF Symposium in Boston (5.–7. Februar 2026) präsentiert. Die 12-Monats-Ergebnisse der VOLT-AF IDE-Studie bestätigen die langfristige Sicherheit und Leistungsfähigkeit des Volt™ Pulsed Field Ablation (PFA) Systems. Zusätzlich wurden positive Daten zur Sicherheit und Wirksamkeit des TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, aus der FOCALFLEX CE Mark Studie vorgestellt. Eine weitere Präsentation zu Abbott's Amulet Gerät aus der VERITAS Amulet 360 Pivotal Study ist für den 6. Februar 2026 geplant.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief via PR Newswire (Ref. ID: CG81045) on February 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}